JMP Securities initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT), noting the company’s initial focus on infectious ...

Opdivo gained rapid approval in the US after having gained 'Breakthrough Therapy Designation', and was also identified as a promising innovative medicine (PIM) for lung cancer by the UK's drug ...

Patients with resected stage 3 or 4 melanoma treated with immune-oncology agents demonstrated significantly higher cure rates ...

Bristol-Myers Squibb's Opdivo has been recommended as a treatment for around 3,000 people with rare forms of gastro-oesophageal cancer via the NHS in England and Wales. In final guidance ...

Bristol Myers Squibb Co (NYSE: BMY) released topline data from the Phase 3 CheckMate -67T noninferiority trial of a subcutaneous Opdivo (nivolumab) compared to intravenous (IV) Opdivo for advanced ...

Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration (FDA) for Opdivo to treat adults ...

Treatment with nivolumab reduced the risk of disease recurrence, progression or death by 42% compared with placebo. The Food and Drug Administration (FDA) has approved Opdivo (nivolumab) with ...

Risk of disease recurrence or death was reduced by 42% with Opdivo compared to chemotherapy. 18-month event-free survival was 70% for Opdivo-treated patients, versus 50% for chemotherapy.

Their success is attributed to two of the first PD-1 inhibitors to be approved, Keytruda (pembrolizumab) and Opdivo ...

Bristol Myers Squibb Q3 revenue rose 8% YoY to $11.89 billion, driven by strong Growth Portfolio sales, especially Eliquis.

Bristol Myers Squibb exceeded third-quarter profit expectations with $3.7 billion earnings, due to strong sales in established and new drugs. Revenue climbed 8%, hitting $11.89 billion. However, the ...

Dr Meredith Edwards, Country Medical Director, Bristol Myers Squibb New Zealand, said, “The funding of OPDIVO as a treatment option for previously treated advanced clear cell renal cell carcinoma ...